Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4BIK

Structure of a disulfide locked mutant of Intermedilysin with human CD59

Summary for 4BIK
Entry DOI10.2210/pdb4bik/pdb
DescriptorINTERMEDILYSIN, CD59 GLYCOPROTEIN (2 entities in total)
Functional Keywordscomplement, cholesterol dependent cytotoxin, immune system, membrane attack complex
Biological sourceSTREPTOCOCCUS INTERMEDIUS
More
Cellular locationCell membrane; Lipid-anchor, GPI-anchor: P13987
Total number of polymer chains4
Total formula weight136522.69
Authors
Johnson, S.,Brooks, N.J.,Smith, R.A.G.,Lea, S.M.,Bubeck, D. (deposition date: 2013-04-10, release date: 2013-05-08, Last modification date: 2024-11-13)
Primary citationJohnson, S.,Brooks, N.J.,Smith, R.A.G.,Lea, S.M.,Bubeck, D.
Structural Basis for Recognition of the Pore- Forming Toxin Intermedilysin by Human Complement Receptor Cd59
Cell Rep., 3:1369-, 2013
Cited by
PubMed Abstract: Pore-forming proteins containing the structurally conserved membrane attack complex/perforin fold play an important role in immunity and host-pathogen interactions. Intermedilysin (ILY) is an archetypal member of a cholesterol-dependent cytolysin subclass that hijacks the complement receptor CD59 to make cytotoxic pores in human cells. ILY directly competes for the membrane attack complex binding site on CD59, rendering cells susceptible to complement lysis. To understand how these bacterial pores form in lipid bilayers and the role CD59 plays in complement regulation, we determined the crystal structure of human CD59 bound to ILY. Here, we show the ILY-CD59 complex at 3.5 Å resolution and identify two interfaces mediating this host-pathogen interaction. An ILY-derived peptide based on the binding site inhibits pore formation in a CD59-containing liposome model system. These data provide insight into how CD59 coordinates ILY monomers, nucleating an early prepore state, and suggest a potential mechanism of inhibition for the complement terminal pathway.
PubMed: 23665225
DOI: 10.1016/J.CELREP.2013.04.029
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.494 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon